Pediatric Expanded Access Program-Oral Solution (0831-908)

Summary

Monitor the safety and tolerability of efavirenz oral solution in combination with Antiretroviral Therapy for the treatment of patients age 3 to 16 years who have failed therapy or who are intolerant to their current therapy. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Timeline

Start

2001-03

Primary completion

2002-12

Completion

2002-12

Drugs

Indications